STDR
Singapore Therapeutics Development Review

ANNEX A

EVALUATION CRITERIA FOR STDR PILOT STAGE

S/N	Criteria
1	**Research and Scientific Merit of technology**
1.1	**Current Scientific Understanding of Target and Platform Validation** • Evidence to support the proposed target as a driver of disease • Evidence to substantiate proposed mechanism of action (MOA) of disease treatment • For platforms: Evidence to support the platform and what is the breadth of applications
1.2	**Quality of Research Conducted to Date** • Stage of development of the technology; and the corresponding development, reasoning, and appropriateness of the concepts and methodology
1.3	**Potential as Platform Technology [For platform projects]** • Potential to be developed as a platform technology for multiple products or indications • Opportunity matrix of possible therapies that can be developed using this platform
2	**Medical Need and Market Evaluation**
2.1	**Unmet Medical Need and Current Market Size** • Prevalence of the indication • Size of the potential target population • Potential of the technology to deliver on the unmet medical need • For platforms: Spectrum of possible indications and size of the first target indication
2.2	**Research Differentiation** • Existence of directly competing technologies in development, or groups known to be working on similar technologies or the same targets • Stage of development of the competing groups vis-à-vis the proposed research • Medical expertise in team, either through experience or collaboration
2.3	**Competitive Landscape** • Amount of commercial competition in the target indication, including other treatment approaches (e.g. surgery or devices) • Existence of therapeutics being developed for the target in the same or different indications • Clarity on the benefits over current standard of care
3	**Development Plans**
3.1	**Research Plan Feasibility** • Realistic deliverables with respect to the timeframe and proposed budget • Realistic and quality research plan with a clear roadmap • Presence of any significant barriers to achieving stated goals • Sufficient budget, expertise and access to research infrastructure or resources • Clear identification of go/no-go criteria

4	**Commercialisation and Intellectual Property (IP)**
4.1	**Commercial Viability** • Ability of proposed deliverables to position the project for the next funding stage or be attractive to commercial partners • Amount of additional development and/or budget outlay to support future development • Time taken for technology to be ready for pre-Investigational New Drug (IND) activities and/or clinical development • Challenges in-terms of scaling-up, manufacturing and deployment/clinical adoption of the asset or platform technology
4.2	**Intellectual Property** • How crowded the patent landscape is • Potential to generate foreground IP • Potential issues with freedom-to-operate
4.3	**Strategic Partnerships for Future Development** • Identification or engagement of strategic partners • Potential for development of technologies with partners • Development plan to secure venture capital funds • Strategy for licensing